A CRISPR Solution to Eliminating Muscular Dystrophy | Stories | PerkinElmer
珀金埃尔默网站上的Cookie
珀金埃尔默使用cookies来确保我们为您提供在我们网站上的最佳体验。 这可能包括来自第三方网站的cookies。 如果您不改变您的设置点击继续,我们会认为您同意接收本网站的cookies。 您可以随时更改您的Cookie设置。 要了解更多信息,请查看我们的Cookie政策,其中包含有关如何管理Cookie的信息。

A CRISPR Solution to Eliminating Muscular Dystrophy

August 19, 2015

Muscular Dystrophy

Background

When it comes to Duchenne muscular dystrophy (DMD), there is rarely good news to share. It is an inherited disorder caused by the mutation of a gene that makes dystrophin, a protein on the X chromosome needed for healthy muscle development. Without it, victims suffer progressively worsening muscle failure beginning in early childhood. By the time they reach puberty, 90% of DMD victims cannot walk. By their mid-20s, most are dead – victims of an incurable disorder that finally shuts down their ability to breathe or their hearts to beat.1

Biology 101

Thanks to something called X-linked recessive inheritance, every boy inherits an X chromosome from his mother and a Y chromosome (which makes him male) from his father. Girls inherit two X chromosomes, one from each parent.2

Both boys and girls have a 50/50 chance of inheriting the protein disorder if their mother has the dystrophin mutation. Most girls never develop DMD, but they are carriers of the disorder and may likely suffer from cardiomyopathy, or weakening of the heart muscle, later in life. Boys with the flawed gene lack the protection of that second X chromosome and constitute the vast majority of DMD sufferers. By one estimate, 1 in every 2,400 boys worldwide is born with DMD. By the age of five, most are already suffering from the relentlessly progressive muscle-wasting disease. There are no cures, no treatments, and no survivors.3

Of Mice and Men

Don’t tell that to a team of researchers at The University of Texas Southwestern Medical Center in Dallas. They recently developed a new plasmid-based technique using CRISPR/Cas9-mediated genome editing to eliminate defective dystrophin mutations from DNA in mice, which develop similar DMD symptoms to humans. CRISPR (clustered regularly interspaced short palindromic repeat) Cas (CRISPR-associated) systems are a revolutionary approach to alter an organism's complete set of DNA, including all of its genes. It does so by targeting and cutting the DNA chain at a specific site to remove the mutated gene. The double-strand break in the DNA is then repaired by one of two pathways. The first pathway is known as Non-Homologous End-Joining (NHEJ), meaning the broken ends are tied off in the cell. The second pathway is called Homology Directed Repair (HDR). It is based on a DNA template that is injected into the cells of mice zygotes. Zygotes are the earliest developmental stages of fertilized eggs. The treated mice zygotes were then implanted into surrogate mothers. Now carrying the correct DNA template, it knows exactly which DNA sequence to use to repair the cut DNA. The result is an error-free restoration of the DNA strand minus the mutated gene.4

Why is this so important? Unlike other therapies meant to supplant or bypass the defective gene, the CRISPR/Cas9-mediated genome editing approach created by the UT Southwestern Medical Center team eliminates the dystrophin mutation defect completely. It is not simply a work-around; it is a cure… at least in mice. "Even in mice with only a small percentage of corrected cells, we saw widespread and progressive improvement of the condition over time, likely reflecting a survival advantage of the corrected cells and their contribution to regenerating muscle," Dr. Eric Olson, Director of the Hamon Center for Regenerative Science and Medicine at UT Southwestern and Chairman of Molecular Biology, said in a UT press release.5, 6

Scaling Up a Possible Cure in Humans

Dr. Olson is the first to point out that his team’s genomic editing approach is currently not a fix for DMD in people. Technical challenges remain before that becomes a reality. Most important is how to scale up the CRISPR treatment for humans. It is no longer a question of how, but by how much, another team member says, adding that the UT team is already working on a more clinically possible method to correct mutations in adult tissue.

Dr. Olson notes that the current CRISPR technique could well lead to new treatments for DMD sufferers. “…in the future we might be able to use this technique therapeutically… to directly target and correct the mutation in muscle stem cells and muscle fibers,” he says.7

In addition, UT Southwestern Medical Center researchers made another important discovery while testing their CRISPR technique on mice. Correction of only 17% of the mutant protein was enough to allow dystrophin expression in a majority of muscle fibers in the mice. That suggested a “selective advantage” of the corrected skeletal muscle cells, as shown with subsequent Western blot analysis testing that verified that MDM was effectively eradicated in the mice.8 The team also performed a series of cellular and muscle tissue analyses to verify their findings. These included capturing a large number of critically important specimen images using PerkinElmer’s OpenLab 4.0 acquisition and control software. OpenLab software was also used to magnify and color the slides to create image overlays.9

Building On a Strong Relationship

The UT Southwestern Medical Center is one of the foremost academic and research centers in the U.S. In addition to the OpenLab software, PerkinElmer supports the Center with a number of analytical and imaging instruments, including an Operetta® high-content microplate imaging solution, a Vectra® automated quantitative pathology imaging system, a LabChip® GXII Touch for genomics instrument, as well as EnVision® plate readers for research and assay development applications.

 

References

  1. Prevention of muscular dystrophy in mice by CRISPR/Cas9–mediated editing of germline DNA, Science, published online August 14, 2014.
  2. X-Linked Recessive Inheritance – Traditional Patterns of Inheritance 3 (Fact Sheet 10), New South Wales (Australia) Government Ministry of Health – Centre for Genetics Education.
  3. Duchenne Muscular Dystrophy Research Fund (DMDfund).
  4. CRISPR gene therapy prevents muscular dystrophy, leahcanscience.com.
  5. Ibid.
  6. New gene editing method shows promising results for correcting muscular dystrophy, Newsroom, The University of Texas Southwestern.
  7. Ibid.
  8. Ibid.
  9. Supplementary Materials for Prevention of muscular dystrophy in mice by CRISPR/Cas9 – mediated editing of germline DNA, Science.

更多故事关于 疾病研究, 新闻, 生命科学, 成像

珀金埃尔默公布2018年第四季度及全年财务业绩

美国马萨诸塞州沃尔瑟姆——致力于创建更健康世界的全球技术领导企业珀金埃尔默(纽约证交所证券代码:PKI)日前公布了其截至2018年12月30日的第四季度和全年财务业绩报告。

珀金埃尔默ICP-MS全球产品团队访问环境化学与生态毒理学国家重点实验室

珀金埃尔默公司电感耦合等离子体质谱仪(ICP-MS)全球产品经理Fadi Abou-Shakra博士一行访问环境化学与生态毒理学国家重点实验室。重点实验室副研究员曲广波对珀金埃尔默团队一行表示了热烈的欢迎。双方人员就合作意向和未来发展方向深入交流意见,确定了基本合作模式。

珀金埃尔默携生物大分子制药方案亮相2018生物制品年会

中国生物制品年会作为学界一年一度最重要的活动,引起了广泛的行业关注。今年生物制品年会于11月15-16日在气候宜人的“春城”昆明举行,本次活动围绕“新型生物技术药研发与评价”、“新型疫苗研发与评价”、“基因与细胞治疗研发与评价”、“生物制药投融资”、“生物制药工程与数字信息化”展开,为2000余位参会代表带来近100场主...

珀金埃尔默在analytica China 2018上载誉归来

经过三天的热闹与相聚,慕尼黑(上海)生化分析展于11月2日落下帷幕。珀金埃尔默展出的仪器覆盖原子光谱、色谱、材料表征、联用技术、生命科学等产品线。除此之外,还有众多行业解决方案、OneSource一站式实验室服务、试剂与耗材等配套服务。

感谢有你——再聚慕尼黑分析生化展

此次珀金埃尔默在慕尼黑生化展上展出了ICP-MS NexIon 2000, ICP-OES Avio 500,高内涵分析系统Operetta CLS及新品荧光分光光度计FL 6500等共计10余台仪器。